To analyze the usage of “dual channel” drugs in designated pharmacies and medical institutions, and to provide a basis for better implementation of the national negotiation drug “dual channel” management mechanism.

The relevant policies of the “dual channel” management mechanism for Shanghai medical insurance were reviewed. The growth rate and coverage of “dual channel” drug costs, the proportion of different types of drug costs, and the ranking of drug costs within the Shanghai medical security intelligent supervision system from January 2022 to December 2023 were analyzed.

The cost of medication costs have increased significantly with the expansion of the scope of “dual channel” management drugs. Antitumor drugs account for the highest cost proportion among all “dual channel” drugs. There were some problems in the implementation of the policy, such as difficulties in prescription circulation, security vulnerabilities in medical insurance funds caused by paper prescriptions.

Since the implementation of the“dual channel” management mechanism, the supply guarantee level of the national negotiation drug has been effectively improved through two different channels of designated pharmacies and medical institutions. To further demonstrate policy effects, it is recommended to strengthen the allocation of “dual channel” drugs, increase the service layout of designated pharmacies and strengthen the supervision of drug usage.